Committed to providing exceptional care and continued support to patients, families and caregivers.

Menu

NCT02500199

Disease Type: Breast
Status: Pending

Trial Information

A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients whose disease progressed on prior HER2 targeted therapy

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact: